Vector Core (Core 2) The Vector Core at the University of Iowa serves multiple projects directed at the study of cystic fibrosis and therapy development. The interaction with multiple investigators from various disciplines allows for cross- fertilization of ideas, technical advancements, and innovations in vector designs. The overall objective of the Vector Core is to support investigators in generating and implementing gene delivery and gene editing technologies. This includes consultation with the Principle Investigator, development of novel vectors, and routine vector preparation. The Core staff and investigators are in close contact through all phases of vector design and generation. Thus, the Core serves as both a research & development facility for gene transfer studies and a service facility for routine vector preparations. The Core provides purified and concentrated preparations of recombinant adenovirus, adeno-associated virus (AAV), vaccinia, baculovirus and retrovirus (including lentivirus). These vectors have proven success at delivering therapeutic transgenes or CRISPR- based technologies to airway cells. Additional services include access to standard cell lines, expression plasmids, and stocks of reporter viruses. The main responsibilities of the Vector Core will be: Viral Vector Production Research and Development Education Materials Archive Delivery vectors for gene replacement or genome engineering strategies in airway epithelia could confer long- term correction of the CF phenotype. In addition, such vectors can be used for hypothesis driven research such as labeling progenitor cells within the airways. There have been important advancements in approaches to rescue CFTR protein function. However similar therapies for the most common mutation is not yet available. The goal of the Vector Core is to provide support for researchers working to develop a life-long gene replacement strategy that would be efficacious regardless of the disease causing mutation. The Core specializes in gene transfer and gene editing technologies that provide Principle Investigators with delivery vehicles for therapeutic genes such as CFTR. The reagents, methods, and guidance generated by this core provide an important service addressing CF therapies.
| Gray, Robert D; Hardisty, Gareth; Regan, Kate H et al. (2018) Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax 73:134-144 |
| Rosen, Bradley H; Chanson, Marc; Gawenis, Lara R et al. (2018) Animal and model systems for studying cystic fibrosis. J Cyst Fibros 17:S28-S34 |
| Diehl, Lauri; Meyerholz, David K; Day, Michael J et al. (2018) Pathology and Pathogenesis of Immune-Mediated Diseases of Animals. Vet Pathol 55:5-7 |
| Caswell, Jeff L; Bassel, Laura L; Rothenburger, Jamie L et al. (2018) Observational Study Design in Veterinary Pathology, Part 2: Methodology. Vet Pathol 55:774-785 |
| Trillo-Muyo, Sergio; Nilsson, Harriet E; Recktenwald, Christian V et al. (2018) Granule-stored MUC5B mucins are packed by the non-covalent formation of N-terminal head-to-head tetramers. J Biol Chem 293:5746-5754 |
| Yoshida, Mitsuteru; Oishi, Hisashi; Martinu, Tereza et al. (2018) Pentraxin 3 deficiency enhances features of chronic rejection in a mouse orthotopic lung transplantation model. Oncotarget 9:8489-8501 |
| Thornell, Ian M; Li, Xiaopeng; Tang, Xiao Xiao et al. (2018) Nominal carbonic anhydrase activity minimizes airway-surface liquid pH changes during breathing. Physiol Rep 6: |
| Clippinger, Amy J; Allen, David; Behrsing, Holger et al. (2018) Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity. Toxicol In Vitro 52:131-145 |
| Cheng, Sunny Lihua; Li, Xueshu; Lehmler, Hans-Joachim et al. (2018) Gut Microbiota Modulates Interactions Between Polychlorinated Biphenyls and Bile Acid Homeostasis. Toxicol Sci 166:269-287 |
| Cooney, Ashley L; McCray Jr, Paul B; Sinn, Patrick L (2018) Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes (Basel) 9: |
Showing the most recent 10 out of 669 publications
